210 King Street
San Francisco, CA 94107
Stem Cell Agency Legislative Subcommittee Meeting - November 8th, 2010
State Stem Cell Agency Meeting Notice and Agenda
OF THE INDEPENDENT CITIZENS’ OVERSIGHT COMMITTEE
TO THE CALIFORNIA INSTITUTE FOR REGENERATIVE MEDICINE
Organized Pursuant to the
CALIFORNIA STEM CELL RESEARCH AND CURES ACT
1. Call to Order
2. Roll Call
[Members of the Public will be invited to provide testimony before or during consideration of each agenda item. Speakers are asked to limit their testimony to three (3) minutes.]
3. Consideration of federal legislative initiatives regarding stem cell research.
H.R. 4808 (DeGette, "Stem Cell Research Advancement Act of 2009")
S. 3766 (Specter, "Stem Cell Research Advancement Act of 2010")
Letters to Congress from Leaders of Academic Medicine
4. Public comment.
THE ORDER OF BUSINESS MAY BE CHANGED WITHOUT NOTICE.
Notice is hereby given that the order of consideration of matters on this agenda may be changed without prior notice.
The California Institute for Regenerative Medicine and its Independent Citizens Oversight Committee, and any subcommittees thereof, comply with the Americans with Disabilities Act (ADA) by ensuring that the meeting facilities are accessible to persons with disabilities, and providing that this notice and information given to the Members of the Committee is available to the public in appropriate alternative formats when requested. If you need further assistance, including disability-related modifications or accommodations, you may contact Melissa King at the California Institute for Regenerative Medicine at 415-396-9100 no later than the day prior to the meeting.
Questions or requests for additional information prior to the Independent Citizens Oversight Committee meeting may be referred to Melissa King at the California Institute for Regenerative Medicine at firstname.lastname@example.org or 415-396-9100.
This meeting agenda is also available on the website for the California Institute for Regenerative Medicine at http://www.cirm.ca.gov .